Nirvana Life Sciences Inc. Contracts Stratus Designs for Mechanical Service to Laboratory

Nirvana Life Sciences Inc. Contracts Stratus Designs for Mechanical Service to Laboratory

Nirvana Life Sciences Inc. (CSE: NIRV)  (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce that it has engaged Stratus Designs Ltd. to undertake design of mechanical and control systems for its Vancouver Lab facility.

Adam Clarke, CEO and Principal Consultant of Stratus commented, "The projects that Nirvana Life Sciences are advancing represent the evolution of modern medicine. Our team will work to ensure that this facility is built to deliver the highest standard of quality for all these initiatives".

Mr. Bruce Clark, Chief Executive Officer of Nirvana commented, "We continue to advance our project, and are pleased that Adam Clarke and the Stratus Design team has chosen to join with us. The expertise he brings in Controls, Automation and Facility Design will be a tremendous asset to our development."

About Stratus Designs Ltd.

Stratus Designs is a BC based automation and mechanical design consultancy that has provided service to more than 40 facilities across Food, Pharmaceutical and Cannabis Industries. Their planning and design services provide crucial guidance through construction and operations phases, resulting in a facility that is optimized for quality and productivity, and designed to meet GACP and GMP standards.

About Nirvana Life Sciences Inc.

Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana's team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.

For further information:
Bruce Clark- CEO
info@nirvanalifescience.com
Phone: 604-401-8100

Forward Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward- looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/120165

News Provided by Newsfile via QuoteMedia

NIRV:CC
The Conversation (0)
Nirvana Life Sciences

Nirvana Life Sciences

Psychedelics for Opioid Addiction Recovery and Pain Management

Psychedelics for Opioid Addiction Recovery and Pain Management Keep Reading...
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has acquired an exclusive... Keep Reading...
Nirvana Life Sciences Announces Approval To Build Vancouver Facility From Health Canada

Nirvana Life Sciences Announces Approval To Build Vancouver Facility From Health Canada

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce that Health Canada has given Nirvana an approval to build out its Research &... Keep Reading...
Nirvana Life Sciences announces filing of Patent for novel isolation of 4-PO-Psilocin Prodrug Compound

Nirvana Life Sciences announces filing of Patent for novel isolation of 4-PO-Psilocin Prodrug Compound

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to report that it has filed a provisional patent application for a novel process for the... Keep Reading...
Nirvana Life Sciences Announces Patent Filing

Nirvana Life Sciences Announces Patent Filing

The Patent Application contains new inventive claims for extraction as well as inventive methods for use of Psilocybin to affect relapse. Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a Canadian based life sciences company focused on developing novel therapeutic products... Keep Reading...
Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

Psilocybin reduced reinstatement of heroin-seeking behavior when administered immediately after a memory retrieval task in ratsNirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian-based life sciences company focused on developing novel therapeutic products derived from... Keep Reading...
Numinus Wellness Announces Change of Auditor

Numinus Wellness Announces Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as... Keep Reading...
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...

Latest Press Releases

Related News